Displaying 1–25 of 10820 results for
Just days after receiving approval in Japan, Daiichi Sankyo said the U.S. FDA will not approve its drug, quizartinib, as a treatment for adults with a type of blood cancer.
Why the industry is forming bonds with CBD
As GlaxoSmithKline readies a spin-off of its consumer healthcare business, the company is looking to shed certain parts of its portfolio.
Merck and Co. is scouting for a replacement for its CEO, Kenneth Frazier.
Online pharmacy Valisure reported that it found a new carcinogenic impurity in some lots of blood pressure medicine valsartan, but the amount is still well below levels the FDA deemed potentially harmful.
Japan is the first country to approve the drug, which targets patients with NTRK fusion-positive solid tumors, across 10 different tumor types.
Sanofi and Google will establish a new virtual Innovation Lab with the ambition to radically transform how future medicines and health services are delivered by tapping into the power of emerging data technologies.
AstraZeneca has promised to invest $630 million into Korea’s biotech and healthcare sector over the next five years.
Pfizer has agreed to buy Array Biopharma in a $10.64 billion cash deal.
As researchers continue to hunt for ways to treat or prevent Alzheimer’s disease, one study has shown promise in slowing the progression of the disease.
Amgen, Eli Lilly and Merck sued the Department of Health and Human Services in an attempt to block new rules requiring that drugmakers disclose the list price of their drugs in television ads
Philadelphia-based Lannett announced it will close its Cody Laboratories subsidiary after failing to find a buyer.
Confidential settlement talks between Novartis and the U.S. government over allegations that the company paid doctors to market drugs were revealed when a letter written to U.S. District Judge was accidentally filed in the court docket.
The buzz may be around biologics, but the oral solid dose sector is still going strong
The Journal of the American Medical Association evaluated top-selling drugs finding that over a six year period, 78 percent of the drugs have seen an increase in costs by more than 50 percent.
The drama surrounding rival treatments for a rare autoimmune disease is mounting.
The FDA observations are piling up for one of India’s biggest generic drug manufacturers.
Supply Chain: The answer to today’s complexities lies in collaborative, sustainable supply chains.
The approval is based on a late-stage trial in which Keytruda showed a significant improvement in overall survival in cancer patients.
Thomas Schinecker is filling the shoes of the retiring Michael Heuer, who was holding the position on an interim basis.
The FDA grants accelerated approval to Roche’s drug combo for lymphoma.
For the first time, researchers have shown that an immunotherapy can temporarily block the development a genetic disease.
Merck & Co. announced it was buying privately held biopharmaceutical company, Tilos Therapeutics, in a deal that could be valued at up to $773 million.